-
2022-09-07
优锐医药助力2022第十一届中国罕见病高峰论坛成功举办
2022年9月2日，第十一届中国罕见病高峰论坛于上海隆重开幕。本届大会以“初心如一 一路同行”为主题，作为国内历史最久，规模最大，影响力最为深远的中国罕见病领域综合性论坛
-
2022-08-18
IND Approval for Ensifentrine Pivotal Clinical Trials for COPD in China
Nuance Pharma announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinical trial of Ens
-
2022-08-09
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces its top-line Phase 3 ENHANCE-2 ("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") trial results evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary d
-
2022-07-26
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
Nuance Pharma announces the completion of dosing for all HNVs in the Phase I clinical study of its novel Ketorolac for IV infusion (NTM-001), a non-opioid analgesic drug co-developed with N
-
2022-07-13
Nuance Pharma advances Rare Disease R&D with CORD
July 11th, 2022, Mr. Mark Lotter, founder and CEO of Nuance Pharma, visited Chinese Organization for Rare Disorders (CORD) and met with Mr. Huang Rufang, founder and president of CORD.
-
2022-06-27
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs
-
2022-06-17
Strategic Cooperation Agreement with SHAPHAR
June 16th, 2022, Nuance Pharma signed Strategic Cooperation Agreement with Shanghai Pharmaceutical Co., Ltd. (Shanghai Pharma).
-
2022-06-09
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Verona Pharma plc (Nasdaq: VRNA) announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-1 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”).
Contact PR
